cardioversion

From Aaushi
Jump to navigation Jump to search

Indications

Management

Notes

More general terms

More specific terms

References

  1. Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 238-40
  2. 2.0 2.1 2.2 Feliciano, Z. In: UCLA Intensive Course in Geriatric Medicine & Board Review, Marina Del Ray, CA, Sept 12-15, 2001
  3. 3.0 3.1 Bellone A et al. Cardioversion of acute atrial fibrillation in the emergency department: A prospective randomised trial. Emerg Med J 2012 Mar; 29:188. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21422032
  4. 4.0 4.1 Goette A, Merino JL, Ezekowitz MD et al. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): A randomised, open-label, phase 3b trial. Lancet 2016 Aug 30; [e-pub]. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27590218 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31474-X/fulltext
    Briasoulis A, Afonso L Do NOACs ENSURE safe cardioversion in atrial fibrillation? Lancet 2016 Aug 30 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27590222 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)31410-6/fulltext
  5. 5.0 5.1 McIntyre WF, Connolly SJ, Wang J et al. Thromboembolic events around the time of cardioversion for atrial fibrillation in patients receiving antiplatelet treatment in the ACTIVE trials. Eur Heart J 2019 Aug 4 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31377776 https://academic.oup.com/eurheartj/article/40/36/3026/5543556